Contact this trialFirst, we need to learn more about you.
CGRP Antagonist
Atogepant for Pediatric Migraine
Recruiting2 awardsPhase 3
Colorado Springs, Colorado
This trial will evaluate the long-term safety and tolerability of atogepant in pediatric participants between ages 6-17 with episodic migraine. 250 participants worldwide will receive atogepant for 52 weeks & will attend regular visits to check for side effects.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service